

Vensun Pharmaceuticals, Inc.: Private Company Information - Bloomberg









































  





















































































July 29, 2017 12:20 AM ET
Pharmaceuticals

Company Overview of Vensun Pharmaceuticals, Inc.



Snapshot People




Company Overview
Vensun Pharmaceuticals, Inc., a pharmaceutical company, develops a portfolio of generic prescription products in various dosage forms for a range of therapeutic categories. It engages in co-developing the products with strategic partners in the United States and overseas. The company was incorporated in 2011 and is based in Yardley, Pennsylvania.


790 Township Line RoadSuite 250Yardley, PA 19067United StatesFounded in 2011



Phone: 215-543-3737

Fax: 215-543-3738

www.vensunrx.com







Key Executives for Vensun Pharmaceuticals, Inc.




Mr. Hemanshu N. Pandya


      	Chief Executive Officer, President and Executive Director
      








Dr. Syed E. Abidi Ph.D.


      	Chairman
      








Mr. Josh Gordon


      	Senior Vice President of Commercial Operations
      








Mr. Kamlesh Haribhakti


      	Chief Scientific Officer, Executive Vice President and Director
      


Age: 59
        







Mr. Dhananjay G. Wadekar


      	Executive Vice President and Director
      


Age: 63
        




Compensation as of Fiscal Year 2017. 

Vensun Pharmaceuticals, Inc. Key Developments

Vensun Pharmaceuticals, Inc. Appoints Joan Janulis as Senior Vice President of Regulatory Affairs and Compliance
Feb 12 16
Vensun Pharmaceuticals, Inc. announced the appointment of Joan Janulis as the Senior Vice President of Regulatory Affairs and Compliance. In this role Ms. Janulis will oversee the regulatory affairs, quality, and compliance functions. Ms. Janulis was most recently a Vice President and Head of the Regulatory Practice at Lachman Consultants.


Similar Private Companies By Industry



Company Name
Region



 1st Order Pharmaceuticals, Inc. United States 21st Century Animal Health United States 3 Buds' Organics LLC United States 4P Therapeutics LLC United States 60° Pharmaceuticals, LLC United States




Recent Private Companies Transactions



TypeDate
Target





Private Placement

			      November 21, 2016
			    
--





Request Profile Update

















 












The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking 
	here.




Stock Quotes


Market data is delayed at least 15 minutes.







Company Lookup



Most Searched Private Companies



Company Name
Geographic Region



 Lawyers Committee for Civil Rights Under Law United States NYC2012, Inc. United States The Advertising Council, Inc. United States Bertelsmann AG Europe Rush University United States













Sponsored Financial Commentaries

Sponsored Links






Browse Companies
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
 | 
0
1
2
3
4
5
6
7
8
9






Request Profile Update

						Only a company representative may request an update for the company profile. Documentation will be required.
					  
To contact Vensun Pharmaceuticals, Inc., please visit www.vensunrx.com.  Company data is provided by S&P Global Market Intelligence.  Please use this form to report any data issues.
					  


Information Missing - Please enter your information in the following field(s): 




Company Name

Your Name*

Your E-Mail Address*

Your Phone Number*

Type of Data*


Overview
Executives
Key developments
Similar companies
Transactions


Update Needed*

All data changes require verification from public sources.  Please include the correct value or values and a source where we can verify.


Cancel


Submit






Your requested update has been submitted
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.


Close





























Vensun Pharmaceuticals, Inc. Completes Series C Financing - MarketWatch



















































Bulletin






Investor Alert























press release


					Dec. 1, 2016, 10:22 a.m. EST
				
Vensun Pharmaceuticals, Inc. Completes Series C Financing






























YARDLEY, Pa., Dec 01, 2016 (BUSINESS WIRE) --
Vensun Pharmaceuticals, Inc. (“Vensun” or “the Company”), a privately 
      held generic pharmaceuticals company, today announced the completion of 
      $22.5 million Series C preferred financing with a consortium of 
      investors led by Perceptive Advisors, LLC. Deerfield Management Company, 
      L.P. also joins Perceptive Advisors as a new investor in the Company. 
      Additional investors in the financing include prior investors JW Asset 
      Management, LLC, Company management and associates, and entities 
      affiliated with Dr. Allen Chao, the co-founder of Watson 
      Pharmaceuticals, Inc., now Allergan plc                 

/quotes/zigman/53242416/composite AGN
-0.45%


. Vensun intends to 
      use the capital for research and development expenses associated with 
      future product development projects as well as working capital needs.


                                        








Mr. Hem Pandya, President and CEO of Vensun commented, “We are excited 
      to enter the next phase of our growth story. The support and confidence 
      shown by our existing investors and the new Series C investors have 
      positioned us well for continued success. This financing will enable 
      Vensun to transform our development pipeline into approved commercial 
      products and provide us with the flexibility to pursue additional growth 
      opportunities.”


                                        








Joseph Edelman, Founder and CEO of Perceptive Advisors remarked, “We are 
      excited to support Vensun as it continues to develop a robust product 
      pipeline.” Michael Altman, Senior Analyst at Perceptive Advisors and 
      newly appointed member to Vensun’s Board of Directors added, “Vensun is 
      expecting a number of new product approvals over the next several years, 
      which position the Company for continued growth.”


                                        








Jason Wild, President and Chief Investment Officer of JW Asset 
      Management and Director of Vensun stated, “As the lead investor in both 
      the Series A and Series B financings, we are excited to strengthen our 
      partnership with Vensun through our participation in the Series C 
      financing. Vensun’s management team has established a strong track 
      record and we are delighted to renew our commitment towards their goal 
      of becoming a leading generic pharmaceutical company.”


                                        








Leerink Partners LLC served as financial advisor to Vensun in the 
      financing. Vensun’s legal advisor is Goodwin Procter LLP. Proskauer Rose 
      LLP acted as legal counsel for Perceptive Advisors, LLC.


                                        

About Vensun Pharmaceuticals, Inc.









Vensun Pharmaceuticals, Inc., based in Yardley, Pennsylvania, was 
      established in July 2011 and is an emerging pharmaceutical company 
      developing a portfolio of generic prescription products in various 
      dosage forms covering a broad range of therapeutic categories. The 
      Company is co-developing the products with a number of strategic 
      partners in the U.S. and overseas. The Company has four ANDAs approved, 
      more than 15 filed ANDAs and has approximately 15 products in active 
      development with various partners. Vensun also in-licensed over 25 
      products to expand and diversify its pipeline.


                                        








For more information regarding Vensun Pharmaceuticals, Inc., please 
      visit         www.vensunrx.com
.


                                        

About Perceptive Advisors, LLC









Founded in 1999 and based in New York, NY, Perceptive Advisors is an 
      investment management firm focused on supporting the progress of the 
      life sciences industry by identifying opportunities and directing 
      financial resources to the most promising technologies in healthcare. 
      For more information about Perceptive Advisors, visit         www.perceptivelife.com
.


                                        

About JW Asset Management, LLC









JW Asset Management, a New York based registered investment adviser, is 
      active in both public and private equity markets. Jason Wild, a 
      registered pharmacist, is the firm's Founder and Chief Investment 
      Officer. JW Asset Management was founded in 2003 and has a strong 
      history of finding opportunities within the specialty pharmaceutical 
      sector.


                                        

About Deerfield Management Company, L.P.









Deerfield is an investment management firm committed to advancing 
      healthcare through investment, information and philanthropy.


                                        








For more information, please visit         www.deerfield.com


THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO SELL OR THE 
      SOLICITATION OF AN OFFER TO BUY ANY SECURITY, NOR SHALL THERE BE ANY 
      SALE, ISSUANCE OR TRANSFER OF SECURITIES OF VENSUN PHARMACEUTICALS, 
      INC., IN ANY STATE IN WHICH SUCH OFFER, SOLICITATION OR SALE WOULD BE 
      UNLAWFUL PRIOR TO REGISTRATION OR QUALIFICATION UNDER THE SECURITIES 
      LAWS OF ANY SUCH STATE.















View source version on businesswire.com:         http://www.businesswire.com/news/home/20161201005887/en/









SOURCE: Vensun Pharmaceuticals, Inc.


                                        








Vensun Pharmaceuticals, Inc.        
Hem Pandya        
President & CEO        
+1-215-543-3737        
www.vensunrx.com









Copyright Business Wire 2016
                    



/quotes/zigman/53242416/composite 





 Add to watchlist
                    
AGN




Allergan PLC


                US
                
                    : U.S.: NYSE
                
            




$
253.01



-1.15
-0.45%




Volume: 1.52M
July 28, 2017 4:02p






P/E Ratio8.70
Dividend Yield1.11%




Market Cap$85.36 billion
Rev. per Employee$882,886





 









 










































Most Popular





1.





Market Extra

Wall Street isn’t ready for a 1,100-point tumble in the Dow industrials






2.






All the companies in Jeff Bezos’s empire, in one (large) chart






3.





Market Snapshot

S&P 500, Nasdaq finish lower after Amazon disappointment; Dow closes at record






4.





MarketWatch First Take

Intel earnings have message for AMD and Nvidia: ‘Bring it on’






5.





SectorWatch

Silicon Valley's corporate-campus building boom is a cautionary tale








Find a Broker

Partner Center »























Featured Stories





Seeing America again through new eyes







How to dig yourself out of debt







Move over, Tesla? Karma unveils its hybrid sports car







The salary you need to afford a home in these 25 cities







Why OPEC will never cut production again













Log In




12:20 AM EDT
July 29, 2017


/marketstate/country/us
New York

	Closed


/marketstate/country/uk
London

	Closed


/marketstate/country/jp
Tokyo

	Closed





/marketstate/country/us
 


/marketstate/country/uk
 


/marketstate/country/jp
 











View All



Latest News

/news/latest
9:16pWall Street isn’t ready for a 1,100-point tumble in the Dow industrials
7:39pBarron's Buzz: Robo 2.0, Facebook and Twitter, Trading On News
7:29pA Wild Week in Washington 
6:32pThe dark side of cruises
6:32pThe highest paid athletes in the world, in one chart
6:31pO.J. Simpson made over $400,000 while in prison and won’t have to give any of it to the Goldman family
6:31p Trump to Police: 'Don't Be Too Nice'
6:31pHere are 10 co-workers you should avoid like the plague — especially in meetings
6:29pTop 10 most annoying people you may want to unfriend on Facebook 
6:29pThis is one person you should never unfriend on Facebook...
6:29p3 horrible ways typos could alter the course of your life
6:27pPaint your bathroom this color and boost your home’s selling price by $5,400
6:27pAmericans’ new badge of honor: ‘I was blocked by a celebrity!’
6:27p5 weird things I found out about America in my first 24 hours 
6:14pBeyond Tesla: 7 stocks driving the autonomous car revolution
6:14pThese 7 highly taxed companies need Congress to finally act on tax reform
6:11pWatch out: ‘Kids’ are making the most money in this stock market 
6:10p7 real ways for millennials to save money (not by brownbagging and skipping Starbucks)
6:09p‘Game of Thrones’: This computer model predicts who will be killed off — or survive
6:09pThis basic balanced index fund is beating the hedge fund averages
Loading more headlines...




dow

/quotes/zigman/627449/realtime
21,830.31

+33.76
+0.15%





nasdaq

/quotes/zigman/12633936/realtime
6,374.68

-7.51
-0.12%





s&p 500

/quotes/zigman/3870025/realtime
2,472.10

-3.32
-0.13%













Kiosk


1352872800000
1352872800000


The RetireMentors






				Retirement advice from our industry experts
				Our team of financial professionals can help you plan and save 
					for retirement, then 
				live well in it.



/conga/kiosk/retirementors.html
361307




1320411600000
1320616500000


Alerts



/conga/kiosk/alerts.html
310238




1333717800000
1333964100000


Virtual Stock Exchange





Our free stock-market game
				• Trade your virtual portfolio in real time
				• Talk strategies in group discussions
				• Find or create a game that suits you
				• Use our learning center to improve 



/conga/kiosk/games.html
310284




1245657600000
1277280000000


Location Scouts




Housing-market insights from our realty pros
																																																							Plus the latest data from Realtor.com on 21 home markets across the U.S.
• See our complete Real Estate site


/conga/kiosk/real_estate.html
357012




1404799200000
1404799200000


Lazy Portfolios





				Set it and forget it
				Check out the returns on our 8 Lazy Portfolios that are made up 
				of low-cost 
				buy-and-hold index funds.

				• How to create your own Lazy Portfolio


/conga/kiosk/lazy_portfolio.html
313134














MarketWatch.com




Site Index
Topics
Help
Feedback
Newsroom Roster

                    Media Archive
Premium Products
Mobile


Company Info
Code of Conduct
Corrections
Advertising Media Kit
Advertise Locally
Reprints & Licensing
Broker Center

                    Your Ad Choices


Follow MarketWatch


































RSS
Podcasts






WSJ.com
Barron's Online
BigCharts
Virtual Stock Exchange


Financial News London
WSJ.com Small Business
realtor.com
Mansion Global












		Copyright © 2017 MarketWatch, Inc.  All rights reserved.
		By using this site, you agree to the Terms of Service,
        Privacy Policy and Cookie Policy.
	



            Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
        






MarketWatch Top Stories
Link to MarketWatch's Slice.

15





























































	Vensun Pharmaceuticals Announces Launch Of Carisoprodol Tablets USP 250 Mg













































Employer:
Login
Post Jobs


Job Seeker:
Login
Sign Up

























Search Life Sciences Jobs





Search Job Title Only












Radius:
Miles



Km80.5
















                 News | News By Subject | News by Disease |  
    News By Date | Search News



















Get Our FREEIndustry eNewsletter

email:


*
            
*
            



















 

 






Vensun Pharmaceuticals Announces Launch Of Carisoprodol Tablets, USP, 250 Mg

  











Tweet








2/3/2016 10:32:24 AM




  Life Sciences Jobs
 


  &bullet; Newest Jobs - Last 24 Hours


  &bullet; California Jobs


  &bullet; Massachusetts Jobs


  &bullet; New Jersey Jobs


  &bullet; Maryland Jobs


  &bullet; Washington Jobs


  View More Jobs



YARDLEY, Pa.--(BUSINESS WIRE)--Vensun Pharmaceuticals, Inc. (“Vensun” or “the Company”), a privately 
      held generic pharmaceutical company, today announced the launch of 
      Carisoprodol Tablets USP, 250 mg, the first generic equivalent to Meda’s 
      Soma® 250 mg Tablets. According to IMS Health, the product 
      had U.S. sales of approximately $16 million for the 12 months ending 
      November 30, 2015.
    
“This is a critical milestone for 
      the company. Carisoprodol is the first product approval from our 
      development portfolio. This marks the first step towards realizing our 
      vision of building an organization that provides affordable and high 
      quality generics while creating value for our customers, partners and 
      stakeholders.”

      Hem Pandya, President and CEO said, “This is a critical milestone for 
      the company. Carisoprodol is the first product approval from our 
      development portfolio. This marks the first step towards realizing our 
      vision of building an organization that provides affordable and high 
      quality generics while creating value for our customers, partners and 
      stakeholders.”
    

      In addition to this product, the Company currently markets 9 products 
      licensed from various partners and has over 20 accepted ANDA filings, 
      representing $2.8 billion in sales, for the 12 months ending November 
      30, 2015, according to IMS Health.
    

About Vensun Pharmaceuticals, Inc.


      Vensun Pharmaceuticals, Inc., based in Yardley, Pennsylvania, was 
      established in July 2011 and is an emerging pharmaceutical company 
      developing a unique portfolio of generic prescription products in 
      various dosage forms covering a broad range of therapeutic categories. 
      The Company is co-developing the products with a number of strategic 
      partners in the US and overseas to leverage economies of scale to 
      efficiently develop products and ultimately supply quality generic 
      products to the marketplace cost effectively. The Company currently has 
      over 20 filed ANDAs and has 14 products in active development. In 
      addition to this proprietary product development program, Vensun has 
      also in-licensed 24 products to expand and diversify its pipeline.
    

      For more information regarding Vensun Pharmaceuticals, Inc. please visit www.vensunrx.com.
    








Contacts


      Vensun Pharmaceuticals, Inc.Hem PandyaPresident & CEO+1-215-543-3737www.vensunrx.com








                Read at
                BioSpace.com







Related News
Vensun Pharmaceuticals Announces Appointment Of Ed Schutter To Its Board Of Directors  Congress Subpoenas Martin Shkreli to Testify About Drug Pricing, Shkreli May Plea the Fifth  Vensun Pharmaceuticals Enters Into Manufacturing, Supply and Distribution Agreement With ScieGen Pharmaceuticals, Inc. Gilead (GILD) Faces Lawsuits over AIDS Drug Patents, Threats of Lawsuits for Hepatitis C Treatments  Emails Reveal Turing, Valeant (VRX) Price Increases Were Basis for Revenue Growth  Off Label Use of Roche (RHHBY)’s Avastin in India Puts 15 in the Hospital, Prompts Officials to Halt Using the Drug  Valeant (VRX) Has Found Another Enemy in Democratic Presidential Candidate Hillary Clinton Pfizer (PFE) Jacked Up Prices of More Than 100 Drugs on Jan. 1  Gilead (GILD) Should Have Investors Giddy Over Continued HCV Dominance at J.P. Morgan Massive Problem Martin Shkreli Zeroed-In On Is Happening Again  




Please enable JavaScript to view the comments powered by Disqus.
comments powered by Disqus






















                            •
                            BioSpace.com










                            •
                            Vensun Pharmaceuticals




             
        





                            •
                            Clinical - Drug Product News




             
        















                              
                            

                              
                             
                              
                            

                              
                            








                 
































Microsoft personalized ad preferences




 













To opt out of personalized ads in this browser, your browser history must allow first-party and third-party cookies and you must have your browsing experience set to NOT delete browsing history on exit. Instructions for enabling cookies and configuring your browsing history may be available in your browsers settings, privacy, or help documentation.

















Sign in
















  Hold on… We’re sorry but this didn’t work.                  You can’t turn off personalized ads right now because your browser is currently blocking third-party cookies. We can help you fix this issue.                Let’s get started:  Depending on what browser you use, open Options or Settings.                  Make sure that third-party cookies are not blocked anymore. To find out how, search your browser’s Help.                                 Revisit http://choice.microsoft.com/opt-out, and then on the “Personalized ads in this browser” tile, click Off.                 ext74081 




  About Our Ads To create a more customized online experience, some of the ads you may receive on Microsoft websites and apps are tailored to your previous activities, searches and site visits. You're in control and here's where you can make the advertising choice that's right for you. ext74075 




  Where Can I Learn More about Advertising on Microsoft Websites and Apps? Microsoft partners with Oath, AppNexus and other third party service providers to help present customized content and display advertisements on MSN, Outlook.com and other websites and apps. Microsoft also delivers search ads to Bing and our search syndication partners. Learn more about Microsoft’s privacy practices here. You can learn more about interest-based ads from Oath and AppNexus in their privacy statements: Oath and AppNexus. What Choices Do I Have About Interest-Based Advertising? On this page, you can opt out of receiving interest based advertising from Microsoft. You can also opt out of receiving interest-based advertising from all self-regulatory members, including Microsoft, Oath, AppNexus and other third party ad networks, at the following sites:  In the US: Digital Advertising Alliance (DAA) In Europe: European Interactive Digital Advertising Alliance (EDAA) In Canada: Ad Choices: Digital Advertising Alliance of Canada (DAAC)  You can control interest-based advertising in Windows apps by turning off the advertising ID in Windows Settings.  More choices  Do you want personalized ads from other companies?  Questions? If you have a privacy question or a question for the Chief Privacy Officer of Microsoft, please contact us by using our web form. We will respond to questions within 30 days. ext74076 




       Personalized ads in this browser     OFF    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting for this web browser.  Learn more           If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.          ext74078 




       Personalized ads wherever I use my Microsoft account     OFF   Sign in to change...    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting that applies when you are signed in on any computer or device with your Microsoft account, including Windows, Windows phone, Xbox and other devices.  Learn more                    If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.         If you choose “generic” ads and use a browser, your choice applies to everyone when using that browser as long as you do not clear your cookies.          ext74079 




       Personalized ads in Windows         In your Windows Settings, you can turn off personalized ads that appear in apps on this device. You’ll still see ads, but they won’t be personalized anymore.     If you have Windows 8.1:            Access the charms by touching or moving your pointer to the right edge of the screen.                 Click or tap Settings, and then click or tap Change PC Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have Windows 10:            Click or tap the Start button.                 Click or tap Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have a Windows mobile device:            Go to Settings.                 Tap on Privacy.                 Tap on Advertising ID, and then turn off Let apps use my advertising ID for experiences across apps.                If you want to turn off personalized ads from Microsoft wherever you use your Microsoft account including apps on Windows, Windows Phone, Xbox and other devices, you can do so by selecting the Microsoft account option above.    ext74080 














Legal
Privacy & Cookies
© 2017 Microsoft






















Bing Places for Business
























































































































Bing
 places for business


Sign in using your




Microsoft Account





Work Account





Google Account





Facebook Account

Don't have an account? Create one.







Vensun Pharmaceuticals, Inc - Generic Pharmaceutical Prescription Drugs















































 Search


phone  215.543.3737
790 Township Line Rd., Suite 250 Yardley, PA 19067





 




Vensun Pharmaceuticals, Inc., based in Yardley, Pennsylvania, was established in July 2011 and is an emerging pharmaceutical company developing a portfolio of generic prescription products in various dosage forms covering a broad range of therapeutic categories. The Company is co-developing the products with a number of strategic partners in the U.S. and overseas. The Company has four ANDAs approved, more than 15 filed ANDAs and has approximately 15 products in active development with various partners. Vensun also in-licensed over 25 products to expand and diversify its pipeline.






Products





Partners





News and Events



















Careers | Vensun Pharmaceuticals, Inc.














































 Search


phone  215.543.3737
790 Township Line Rd., Suite 250 Yardley, PA 19067





 




Careers


Vensun is always seeking dynamic individuals who have the talent, skill set and desire to work in a very high pace environment within the pharmaceutical industry. If you are interested in potentially joining the Vensun team, please email your resume to HR@vensunrx.com . If there is a position available that meets the required qualifications, we will gladly contact you. Vensun is an equal opportunity employer.


















News & Events | Vensun Pharmaceuticals, Inc.










































 Search


phone  215.543.3737
790 Township Line Rd., Suite 250 Yardley, PA 19067





 



News & Events





Posted on April 9, 2015  by  admin 


c
April 2015  Ed Schutter Press Release
Vensun Pharmaceuticals appoints Ed Schutter to its Board of Directors
October 2014  Josh Gordon Press Release
Vensun Pharmaceuticals appoints Josh Gordon as the Senior Vice President of Sales, Marketing and Commercial Operations
August 2014  Vensun ScieGen Agreement Press Release
Vensun Pharmaceuticals has entered into Manufacturing, Supply and Distribution Agreement with ScieGen Pharmaceuticals to commercialize 23 prescription generic products 
June 2014
Vensun Pharmaceuticals files its 20th ANDA
December 2013  Vensun Series B Financing Press Release
Vensun Pharmaceuticals completes a $15.8 million Series B financing led by JW Asset Management, LLC; Vensun Pharmaceuticals files its 10th ANDA
August 2012
Vensun Pharmaceuticals executes a multi-product development & supply agreement with a Bengaluru, India based FDA approved pharmaceutical company.
March 2012
Vensun Pharmaceuticals raises $5.7M in a Series A financing led by JW Asset Management. The company is now established as a Delaware C corp – Vensun Pharmaceuticals, Inc.
February 2012
Vensun Pharmaceuticals executes a multi-product Development & Supply Agreement with a leading Chennai, India based FDA approved pharmaceutical company.
December 2011
Vensun Pharmaceuticals files its 1st ANDA
October 2011
Vensun Pharmaceuticals raises an initial funding of $1.68M
July 2011
Vensun Pharmaceuticals executes a multi-product Development and Supply Agreement with Pharmaceutics International, Inc. (Pii); Vensun Pharmaceuticals, LLC is established as a rapidly emerging pharmaceutical company developing a unique portfolio of generic prescription products in various dosage forms covering a broad range of therapeutic categories.



















About Us | Vensun Pharmaceuticals, Inc.














































 Search


phone  215.543.3737
790 Township Line Rd., Suite 250 Yardley, PA 19067





 




About Us


Executive Management
Board of Directors


















Executive Management | Vensun Pharmaceuticals, Inc.














































 Search


phone  215.543.3737
790 Township Line Rd., Suite 250 Yardley, PA 19067











Executive Management


Hemanshu (Hem) Pandya – President and Chief Executive Officer
Hemanshu (Hem) Pandya – President and Chief Executive Officer
Mr. Pandya is an experienced pharmaceutical executive with a broad spectrum of commercial, operational, strategic and corporate development experience. Previously, Mr. Pandya was President and Chief Executive Officer of IGI Laboratories Inc. (NYSE AMEX: IG) a provider of topical formulation development, analytical, manufacturing and packaging services to the pharmaceutical industry. Prior to IGI, Mr. Pandya was Chief Operating Officer of NexMed Inc. (now Apricus Biosciences Inc – NASDAQ: APRI), responsible for R&D, Operations, and Corporate Development. He has also served in various senior management roles within the pharmaceutical industry including Senior Vice President of Business Development and Strategic Alliances for Andrx Pharmaceuticals (now Watson Pharmaceuticals – NYSE : WPI), Chief Commercial Officer for Putney, Inc., and senior management roles with Able Laboratories, Inc., Ivax Pharmaceuticals, Inc. (now Teva Pharmaceuticals Industries Limited – NYSE : TEVA) and Faulding/Purepac Pharmaceutical Company (now Actavis, Inc.).
Kamlesh Haribhakti – Executive Vice President and Chief Scientific Officer
Mr. Haribhakti has extensive experience in all aspects of pharmaceutical development including formulations, analytical, pharmacokinetics, and regulatory. Mr. Haribhakti has been responsible for successfully developing, filing, and obtaining FDA approval for over 100 generic pharmaceutical products. Previously, Mr. Haribhakti was Managing Director of Dinesh Remedies Limited (DRL). Prior to DRL, Mr. Haribhakti was a Co-Founder and Chief Executive Officer of KVD Pharma until its sale to Amneal Pharmaceuticals in Dec. 2007. He has also served in R&D roles for several pharmaceutical companies throughout his career including Able Laboratories, Inc., McNeil Pharmaceuticals (a Johnson & Johnson company), Eon Laboratories, Inc. (now Sandoz, a Novartis Company), Faulding/Purepac Pharmaceutical Company (now Actavis, Inc.), and Ivax Pharmaceuticals, Inc. (now Teva Pharmaceuticals Industries Limited).
Josh Gordon – Senior Vice President of Sales, Marketing and Commercial Operations
Mr. Gordon is an experienced pharmaceutical executive with a broad array of commercial, operational, strategic and financial experience. Mr. Gordon served in various senior and progressive management roles in the generic pharmaceutical industry including Vice President/General Manager, Specialty Pharmaceuticals at Hospira, Senior Vice President of Purchasing and Operations at Anda, a unit of Andrx Pharmaceuticals (now Actavis) and Vice President of Generic Product Purchasing at Cardinal Health. Prior to joining Vensun, Mr. Gordon was a Vice President at Baxter International, Inc. in their medical products division. Mr. Gordon received his Bachelor’s degree from the University of Pennsylvania’s Wharton School of Business. He earned a Masters of Professional Accounting degree from The University of Miami Graduate School of Business. Mr. Gordon is a Certified Public Accountant.
Joan Janulis – Senior Vice President of Regulatory Affairs and Compliance
Ms. Janulis is a highly experienced pharmaceutical executive with extensive knowledge of U.S. Food and Drug Administration (FDA) regulations, guidance and best practices. Ms. Janulis was most recently a Vice President and Head of the Regulatory Practice at Lachman Consultants, a premier pharmaceutical consulting company.  She also served on Lachman’s board of directors for the past 3 years. Prior to joining Lachman, Ms. Janulis held various executive positions at Faulding/Purepac Pharmaceutical (now Actavis, Inc.  NYSE: ACT), Ivax Pharmaceuticals, Inc. (now Teva Pharmaceuticals Industries Limited – NYSE : TEVA), and Able Laboratories. Ms. Janulis holds a Bachelor of Science degree in Chemical Engineering from the New Jersey Institute of Technology, and has maintained a Regulatory Affairs Certification (RAC) for over 20 years.
Jatin Desai, Ph.D. – Executive Director, R&D and Technical Operations
Dr. Desai is an executive with over 25 years of experience in generic, branded and OTC product development, clinical research and commercialization of products ranging from solid dosage to injectables. His area of expertise is in modified release dosage forms. Dr. Desai has three granted patents and several additional applications under review. Previously, Dr. Desai was the Vice President, Technical Operations at AustarPharma. Prior to AustarPharma, he served in various senior roles as Director of Formulation Research at Zydus Pharmaceuticals, and Vice president Technical Operations at Morepen Laboratories. Dr. Desai holds a Masters of Science degree in Pharmaceutics and Industrial Pharmacy from Lallubhai Motilal College of Pharmacy, India, and a Doctorate in Pharmaceutics from North Gujarat University, India.
Donna M. Cordasco – Senior Director of Quality and Compliance
Ms. Cordasco has over 25 years of diverse experience in pharmaceutical R&D and quality management.  Prior to joining Vensun, Ms. Cordasco was Director of Laboratory QA for the International AIDS Vaccine Initiative, a non-profit organization engaged in novel research and vaccine development.  Her generic pharmaceutical industry experience includes roles as Head of QA/QC & Regulatory at IGI Laboratories, Inc (AMEX: IG) and Director of QA/QC at Sun Pharmaceuticals Industries, Inc. While at Faulding/Purepac Pharmaceutical Company (now Actavis, Inc – NYSE: ACT), she served in several senior management roles including Director of QC, Director of Analytical Services and in various project management, strategic planning, and process improvement  roles. Early in her career, Ms. Cordasco served as an Adjunct Professor in Organic and Biochemistry. Ms. Cordasco has a Bachelor of Science degree in Biochemistry from the University of New Hampshire and a Masters of Science degree in Biochemistry and Molecular Biology from New York University.
George Sager – Director of Operations
Mr. Sager has more than 30 years of Financial and Operational experience. Prior to joining Vensun, Mr. Sager was Controller at Medicia Holdings, LLC, where he managed the day-to-day finance and accounting functions for the contract manufacturer serving the Health and Beauty Industry. Previously, Mr. Sager was Vice President of Finance for Glenmark Pharmaceuticals and has held various positions with companies such as Able Laboratories, Inc., Lederle Laboratories, Asea Brown Boveri, IVC Industries and Guerlain, Inc. Mr. Sager holds a MBA in Finance from Fairleigh Dickinson University and a Bachelor of Science degree in Accounting from Ramapo College.
Rajeev Mohan, Ph.D. – Director of Strategic Development
Dr. Mohan has extensive experience in product development, scale-up, manufacturing, business strategy, product lifecycle management, alliance management and product commercialization. Prior to joining Vensun, Dr. Mohan was Manager of Strategic Analytics supporting the sales and marketing team at Mutual/URL Pharma (now Takeda – NYSE:TKPHF) including the commercial assessment of business development projects. Prior to Mutual, he served in various technical and operational roles including Manager of Manufacturing Systems and Cost Management at Andrx Pharmaceuticals, Inc. (now Actavis – NYSE:ACT).  Dr. Mohan holds a MBA from Cornell University, a Doctorate in Chemical Engineering from Polytechnic University (NYU) and a Bachelor of Science degree in Chemical Engineering from Osmania University, India.


















Vensun Pharmaceuticals, Inc - Generic Pharmaceutical Prescription Drugs















































 Search


phone  215.543.3737
790 Township Line Rd., Suite 250 Yardley, PA 19067





 




Vensun Pharmaceuticals, Inc., based in Yardley, Pennsylvania, was established in July 2011 and is an emerging pharmaceutical company developing a portfolio of generic prescription products in various dosage forms covering a broad range of therapeutic categories. The Company is co-developing the products with a number of strategic partners in the U.S. and overseas. The Company has four ANDAs approved, more than 15 filed ANDAs and has approximately 15 products in active development with various partners. Vensun also in-licensed over 25 products to expand and diversify its pipeline.






Products





Partners





News and Events



















Products | Vensun Pharmaceuticals, Inc.














































 Search


phone  215.543.3737
790 Township Line Rd., Suite 250 Yardley, PA 19067





 




Products


 
AVAILABLE PRODUCTS
Click Product Name below for Prescribing Information



Product
Strength
Brand Reference
NDC
Packaging Size




Sildenafil Tablets, USP 
20 mg
Revatio® Tablets
42543-005-90
90 Count Bottle


Carisoprodol Tablets, USP (C-IV)
250 mg
Soma® Tablets
42543-434-01
100 Count Bottle


Carisoprodol Tablets, USP (C-IV)
350 mg
Soma® Tablets
42543-700-01
42543-700-05
42543-700-10
100 Count Bottle
500 Count Bottle
1000 Count Bottle


Clopidogrel Tablets, USP
75 mg
Plavix® Tablets
42543-713-30
42543-713-90
42543-713-05
42543-713-10
30 Count Bottle
90 Count Bottle
500 Count Bottle
1000 Count Bottle


Donepezil Hydrochloride Tablets, USP
5 mg
.
.
10 mg
Aricept® Tablets
42543-702-30
42543-702-90
42543-702-10
42543-703-30
42543-703-90
42543-703-10
30 Count Bottle
90 Count Bottle
1000 Count Bottle
30 Count Bottle
90 Count Bottle
1000 Count Bottle


Fluoxetine Capsules, USP
10 mg
20 mg
.
40 mg.
Prozac® Capsules
42543-725-01
42543-725-10
42543-726-01
42543-726-10
42543-727-30
42543-727-01
42543-727-05
100 Count Bottle
1000 Count Bottle
100 Count Bottle
1000 Count Bottle
30 Count Bottle
100 Count Bottle
500 Count Bottle


Hydrochlorothiazide Tablets, USP
25 mg
50 mg
Hydrochlorothiazide Tablets
42543-710-10
42543-711-10
1000 Count Bottle
1000 Count Bottle


Levocetirizine Dihydrochloride Tablets
5 mg
Xyzal® Tablets
42543-712-90
90 Count Bottle


Metoprolol Tartrate Tablets, USP
25 mg
50 mg
100 mg
Metoprolol Tartrate Tablets, USP
42543-001-01
42543-001-10
42543-002-01
42543-002-10
42543-003-01
42543-003-10
100 Count Bottle
1000 Count Bottle
100 Count Bottle
1000 Count Bottle
100 Count Bottle
1000 Count Bottle


Nystatin Topical Powder, USP
100,000
USP units
per gram
Nystatin Topical Powder
42543-052-61
42543-052-62
42543-052-63
15 Gram Bottle
30 Gram Bottle
60 Gram Bottle


Pramipexole Dihydrochloride Tablets
0.125 mg
0.25 mg
0.5 mg
0.75 mg
1 mg
1.5 mg
Mirapex® Tablets
42543-704-90
42543-705-90
42543-706-90
42543-707-90
42543-708-90
42543-709-90
90 Count Bottle
90 Count Bottle
90 Count Bottle
90 Count Bottle
90 Count Bottle
90 Count Bottle



Pharmacists, Doctors and Customers: For questions about Vensun Products or to Report Product Complaints or Adverse Events Contact:
1-800-385-1540 or complaints@vensunrx.com
Customers: For questions about Purchase Orders contact Customer Service:
1-800-401-3356 or customerservice@vensunrx.com


















Contact Us | Vensun Pharmaceuticals, Inc.














































 Search


phone  215.543.3737
790 Township Line Rd., Suite 250 Yardley, PA 19067











Contact Us


 
Pharmacists, Doctors and Customers: For questions about Vensun Products or to Report Product Complaints or Adverse Events Contact:
1-800-385-1540 or complaints@vensunrx.com
Customers: For questions about Purchase Orders contact Customer Service:
1-800-401-3356 or customerservice@vensunrx.com
 
Mr. Hem Pandya, President & CEO – hpandya@vensunrx.com
Mr. Kamlesh Haribhakti, EVP & CSO – kharibhakti@vensunrx.com
Mr. George Sager, Director of Operations – gsager@vensunrx.com
Business Development Team – BD@vensunrx.com
Human Resources – HR@vensunrx.com
Investor Relations – IR@vensunrx.com
Corporate Office
Main Telephone Number – 215.543.3737
Fax Number – 215.543.3738
790 Township Line Road
Suite 250
Yardley, PA 19067
Sales Office 
103 Carnegie Center Drive
Suite 300
Princeton, NJ 08540
 













Vensun Pharmaceuticals, Inc. Completes Series C FinancingHomeMailFlickrTumblrNewsSportsFinanceCelebrityAnswersGroupsMobileMoreTry Yahoo Finance on Firefox »YahooSearchSearchSign inU.S. Markets closedS&P 5002,472.10-3.32 (-0.13%)Dow 3021,830.31+33.76 (+0.15%)Nasdaq6,374.68-7.51 (-0.12%)LISTENWho is the face of pro baseball?Yahoo Finance's Dan Roberts and Myles Udland debate the business of baseballVensun Pharmaceuticals, Inc. Completes Series C FinancingBusiness WireDecember 1, 2016ReblogShareTweetShareYARDLEY, Pa.--(BUSINESS WIRE)--Vensun Pharmaceuticals, Inc. (“Vensun” or “the Company”), a privately held generic pharmaceuticals company, today announced the completion of $22.5 million Series C preferred financing with a consortium of investors led by Perceptive Advisors, LLC. Deerfield Management Company, L.P. also joins Perceptive Advisors as a new investor in the Company. Additional investors in the financing include prior investors JW Asset Management, LLC, Company management and associates, and entities affiliated with Dr. Allen Chao, the co-founder of Watson Pharmaceuticals, Inc., now Allergan plc (AGN). Vensun intends to use the capital for research and development expenses associated with future product development projects as well as working capital needs.Mr. Hem Pandya, President and CEO of Vensun commented, “We are excited to enter the next phase of our growth story. The support and confidence shown by our existing investors and the new Series C investors have positioned us well for continued success. This financing will enable Vensun to transform our development pipeline into approved commercial products and provide us with the flexibility to pursue additional growth opportunities.”Joseph Edelman, Founder and CEO of Perceptive Advisors remarked, “We are excited to support Vensun as it continues to develop a robust product pipeline.” Michael Altman, Senior Analyst at Perceptive Advisors and newly appointed member to Vensun’s Board of Directors added, “Vensun is expecting a number of new product approvals over the next several years, which position the Company for continued growth.”Jason Wild, President and Chief Investment Officer of JW Asset Management and Director of Vensun stated, “As the lead investor in both the Series A and Series B financings, we are excited to strengthen our partnership with Vensun through our participation in the Series C financing. Vensun’s management team has established a strong track record and we are delighted to renew our commitment towards their goal of becoming a leading generic pharmaceutical company.”Leerink Partners LLC served as financial advisor to Vensun in the financing. Vensun’s legal advisor is Goodwin Procter LLP. Proskauer Rose LLP acted as legal counsel for Perceptive Advisors, LLC.About Vensun Pharmaceuticals, Inc.Vensun Pharmaceuticals, Inc., based in Yardley, Pennsylvania, was established in July 2011 and is an emerging pharmaceutical company developing a portfolio of generic prescription products in various dosage forms covering a broad range of therapeutic categories. The Company is co-developing the products with a number of strategic partners in the U.S. and overseas. The Company has four ANDAs approved, more than 15 filed ANDAs and has approximately 15 products in active development with various partners. Vensun also in-licensed over 25 products to expand and diversify its pipeline.For more information regarding Vensun Pharmaceuticals, Inc., please visit www.vensunrx.com.About Perceptive Advisors, LLCFounded in 1999 and based in New York, NY, Perceptive Advisors is an investment management firm focused on supporting the progress of the life sciences industry by identifying opportunities and directing financial resources to the most promising technologies in healthcare. For more information about Perceptive Advisors, visit www.perceptivelife.com.About JW Asset Management, LLCJW Asset Management, a New York based registered investment adviser, is active in both public and private equity markets. Jason Wild, a registered pharmacist, is the firm's Founder and Chief Investment Officer. JW Asset Management was founded in 2003 and has a strong history of finding opportunities within the specialty pharmaceutical sector.About Deerfield Management Company, L.P.Deerfield is an investment management firm committed to advancing healthcare through investment, information and philanthropy.For more information, please visit www.deerfield.comTHIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY ANY SECURITY, NOR SHALL THERE BE ANY SALE, ISSUANCE OR TRANSFER OF SECURITIES OF VENSUN PHARMACEUTICALS, INC., IN ANY STATE IN WHICH SUCH OFFER, SOLICITATION OR SALE WOULD BE UNLAWFUL PRIOR TO REGISTRATION OR QUALIFICATION UNDER THE SECURITIES LAWS OF ANY SUCH STATE.View source version on businesswire.com: http://www.businesswire.com/news/home/20161201005887/en/ReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextShkreli portrayed as con, prodigy at securities fraud trialAssociated PressThis Will Be In Everyone's Household By 2020Banyan HillSponsoredHow fentanyl is making the opioid epidemic even worseVoxJury to Soon Begin Deliberations in 'Pharma Bro' Martin Shkreli's Fraud TrialFortuneMartin Shkreli's lawyer says former drug company chairman tried to 'seduce' the 'pharma bro'CNBCEngineer Finds Pattern; Makes Millions in StocksMoney MorningSponsoredThe Senate probe into big pharma's hand in the opioid crisis just got biggerBusiness InsiderThe 'two pizza rule' is a secret to productive meetings that helped Amazon CEO Jeff Bezos become one of the world's richest menBusiness InsiderHere are the US targets North Korea most likely wants to nukeBusiness InsiderDiscover it: 4.8 out of 5 avg. by 24K+ customersDiscover CardSponsoredThe real reason overseas manufacturing is coming to AmericaYahoo FinanceCryptocurrency ICOs Are Making Bitcoin Startups Richer than VCs Ever DidFortuneChevron and Exxon Mobil have a tough path ahead: NYSE traderYahoo Finance VideoWhat's the Problem with Joel Osteen?ChurchLeaders.comSponsoredStocks mixed after heavy earnings weekAPNewsBreak: Yellowstone park cracks down on sex harassmentAssociated PressStruggling to govern, Trump faces growing Republican uneaseStuart: Actually this is the best our country can do right now.  If the Republicans accomplished anything it would be tax cuts for the wealthy, cuts to Medicaid, Medicare and Social Security, removal of all banking regulations and environmental protections and on and on.

Get rid of these traitors in 2018 so our country can be great again.Join the Conversation1 / 51.3k








